– USA, IL – Baxter International Inc. (NYSE: BAX), a global MedTech leader, today announced the appointment of Steve Rusckowski to its Board of Directors effective immediately.
“We are pleased to welcome Steve to Baxter’s board,” said José (Joe) E. Almeida, chairman, president and CEO. “His exemplary operational expertise, track record as a transformational leader, and distinguished career as a strategic operational executive will enhance our current board membership. I’m confident Steve’s patient-centric approach will further advance our Mission to Save and Sustain Lives.”
Mr. Rusckowski has also joined the Compensation and Human Capital, and Quality, Compliance, and Technology Committees.
In addition, the company has announced that Mike Mahoney will be resigning from the board effective Sept. 13, 2023.
About Stephen H. Rusckowski
Mr. Rusckowski most recently served as chairman, president, and CEO of Quest Diagnostics, Inc. Before joining Quest Diagnostics, he was CEO of Philips Healthcare, and earlier in his career held roles of increasing responsibility at Hewlett-Packard Company and Procter & Gamble Company. Mr. Rusckowski currently serves as a director of Tenet Healthcare Corporation and Qiagen Inc. and previously served as a member of the boards of directors of Xerox Holdings Corporation, Covidien plc, and MedQuist, Inc. He earned a bachelor’s degree in mechanical engineering from Worcester Polytechnic Institute and a Master of Management Science from the Massachusetts Institute of Technology’s Sloan School of Management.
About Baxter
Every day, millions of patients, caregivers, and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital, and surgical products used across patient homes, hospitals, physician offices, and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions, and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.
SOURCE: https://www.baxter.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.